Effect of tranexamic acid in improving the lifespan of naturally aging mice.


Journal

Inflammopharmacology
ISSN: 1568-5608
Titre abrégé: Inflammopharmacology
Pays: Switzerland
ID NLM: 9112626

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 20 05 2019
accepted: 18 06 2019
pubmed: 27 6 2019
medline: 22 4 2020
entrez: 26 6 2019
Statut: ppublish

Résumé

An effective method to improve lifespan is not known. Therefore, in this study, we examined the lifespan-extending effect of tranexamic acid in normal mice. We bred hairless mice without exposure to ultraviolet radiation and psychical stress until they died naturally. During the study period, the mice were orally administered tranexamic acid (12 mg/kg/day) three times weekly. An increase in the lifespan of mice was observed by tranexamic acid administration. Furthermore, age-related diseases of the skin were ameliorated by tranexamic acid administration. Moreover, the blood level of tumor necrosis factor-α, interleukin-6, reactive oxygen species (ROS), and matrix metalloproteinase (MMP)-9 was decreased by tranexamic acid administration. These results indicate that tranexamic acid suppresses the secretion of inflammatory cytokines, MMP-9, and ROS induced by natural aging, ameliorating age-related diseases, and, consequently, extending the lifespan.

Identifiants

pubmed: 31236768
doi: 10.1007/s10787-019-00616-2
pii: 10.1007/s10787-019-00616-2
doi:

Substances chimiques

Interleukin-6 0
Reactive Oxygen Species 0
Tumor Necrosis Factor-alpha 0
Tranexamic Acid 6T84R30KC1
Matrix Metalloproteinase 9 EC 3.4.24.35

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1319-1323

Subventions

Organisme : JSPS KAKENHI
ID : Grant Number 18K11085

Références

J Immunol. 2014 Oct 15;193(8):4235-44
pubmed: 25217168
J Gerontol A Biol Sci Med Sci. 2014 Jun;69 Suppl 1:S4-9
pubmed: 24833586
J Biol Chem. 2011 Sep 16;286(37):32231-43
pubmed: 21795691
Biomed Pharmacother. 2018 Nov;107:54-58
pubmed: 30081203
Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):15034-9
pubmed: 17848507
Nat Rev Immunol. 2013 Dec;13(12):875-87
pubmed: 24157572
EMBO Mol Med. 2017 May;9(5):622-637
pubmed: 28264935
Nihon Yakurigaku Zasshi. 1967 Nov 20;63(6):560-71
pubmed: 5627190
Cytokine Growth Factor Rev. 2011 Apr;22(2):83-9
pubmed: 21377916
J Immunol. 2009 Jul 15;183(2):1393-402
pubmed: 19553526
Mol Biol Cell. 2002 Dec;13(12):4279-95
pubmed: 12475952
Nihon Shokakibyo Gakkai Zasshi. 2011 Aug;108(8):1374-82
pubmed: 21817840
Arch Dermatol Res. 2019 Sep;311(7):545-553
pubmed: 31147768
Anaesthesiol Intensive Ther. 2015;47(4):339-50
pubmed: 25797505
Nihon Ronen Igakkai Zasshi. 2017;54(2):105-113
pubmed: 28592728
Stroke. 2005 Sep;36(9):1954-9
pubmed: 16051896
Nihon Rinsho Meneki Gakkai Kaishi. 2008 Apr;31(2):104-12
pubmed: 18446013
J Invest Dermatol. 1983 Apr;80(4):297-9
pubmed: 6339645

Auteurs

Keiichi Hiramoto (K)

Department of Pharmaceutical Sciences, Suzuka University of Medical Science, 3500-3, Minamitamagakicho, Suzuka, Mie, 513-8670, Japan. hiramoto@suzuka-u.ac.jp.

Yurika Yamate (Y)

Department of Pharmaceutical Sciences, Suzuka University of Medical Science, 3500-3, Minamitamagakicho, Suzuka, Mie, 513-8670, Japan.

Daijiro Sugiyama (D)

R&D Department, Daiichi Sankyo Healthcare Co., Ltd., Chuo-ku, Tokyo, Japan.

Kazunari Matsuda (K)

R&D Department, Daiichi Sankyo Healthcare Co., Ltd., Chuo-ku, Tokyo, Japan.

Yasutaka Iizuka (Y)

R&D Department, Daiichi Sankyo Healthcare Co., Ltd., Chuo-ku, Tokyo, Japan.

Tomohiko Yamaguchi (T)

R&D Department, Daiichi Sankyo Healthcare Co., Ltd., Chuo-ku, Tokyo, Japan.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH